Cacaito, in a breathtaking display of illogic says:
<<Bruce, You are right and you proved what I am trying to say, that after the good news (FDA approval) then the same hypers created the big drop>>
There is no doubt that I am right. All one needs do is peruse the news stories and price action re Vivus. To say that this proves what you said, is farcical. Vivus reached $1.2 billion in market cap after approval, not before. If Zonagen should follow the same pattern, it would reach $100 per share before your entry point. If you believe your own premise, you would be loading up on Zonagen now!!
<<sorry for my abstract thinking. The actual concrete sales in 1996 were $3,021,940.00 >>
Cacaito, your thinking was not abstract. You merely gave false information. Thank you for correcting it, even if you found it necessary to make a lame excuse for your mistake. BTW, if you are trying to value Zona based on current revenues and earnings, then you should not invest in this or any other development stage company.
<<How much market value can this support?>>
Right now, between $400 and $500 million. It will probably be higher after a marketing deal.
<<I am not questioning Von Emster credibility>>
Yes you are, and it is uncalled for. And Cacaito, you're no Warren Buffet!!
<<Mexican sales, it is not a good strategy to win dollars in Mexico?>>
It could be a better strategy to defer marketing anywhere until a deal is finalized. In case you haven't noticed, Zonagen doesn't need the money right now. They will generate far more revenues from Mexico with the help of a major pharma.
<<Besides, the product is off patent, so anybody can sell it if they want, especially Barr Labs who do not care for patents and fight big Pharma patents. >>
You first say it is off patent, then say Barr Labs will sell since they don't care for patents. Why mention that Barr doesn't care for patents if Vasomax is off patent? It sounds to me like you are not sure and are hedging. The fact is that Zonagen has a use patent and a patent pending for their proprietary formulation. What Barr "cares for" is irrelevant. If they violate Zonagen's use patent, they will be sued and in all likelihood, they will lose.
<<I did have good luck in zona at a profit, out too early I did not understood the market ability to create fluffy market value. But, always something to learn. >>
Obviously, the profit you made in Zona was due to luck and yes, you do have a lot to learn.
Speaking of luck, how's Vivus? Best regards, and do be careful! |
